Comparison of hippocampal G protein activation by 5-HT1A receptor agonists and the atypical antipsychotics clozapine and S16924

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 368, Issue 3, 2003, Pages 188-199

  Newman Tancredi, A ^a,b   Rivet, J M ^a   Cussac, D ^a   Touzard, M ^a   Chaput, C ^a   Marini, L ^a   Millan, M J ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

5 HT1A; 35S GTP S; Atypical antipsychotics; Clozapine; G proteins; Hippocampus; Receptors; S16924; Ziprasidone

Indexed keywords

1 (1,4 BENZODIOXAN 5 YL) 4 (2 INDANYL)PIPERAZINE; 1 [2 (4 FLUOROBENZAMIDO)ETHYL] 4 (7 METHOXY 1 NAPHTHYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO N [2 [4 (METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N 2 PYRIDINYLBENZAMIDE; ALPHA [1 [2 (1,4 BENZODIOXAN 5 YLOXY)ETHYL] 3 PYRROLIDINYL] 4 FLUOROACETOPHENONE; BENZAMIDE DERIVATIVE; BRAIN PROTEIN; BUSPIRONE; CLOZAPINE; ELTOPRAZINE; FLESINOXAN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; PINDOLOL; SEROTONIN 1A AGONIST; SPIPERONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENTATE GYRUS; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HIPPOCAMPUS; HUMAN; MEMBRANE; MOLECULAR CLONING; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SEPTUM PELLUCIDUM; SYNAPSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; CELL MEMBRANE; CHO CELLS; CLOZAPINE; CRICETINAE; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HIPPOCAMPUS; LIGANDS; MALE; PYRROLIDINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN;

EID: 0141958927     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-003-0788-2     Document Type: Article

References (59)

1. 35S]GTPγS binding in rat hippocampal membranes. Eur J Pharmacol 343:303-312
2. 1A receptors in hippocampal and cortical homogenates. Eur J Pharmacol 390: 67-73
3. 1A receptor agonist properties of the antipsychotic nemonapride: comparison with bromerguride and clozapine. Eur J Pharmacol 334:141-147
4. 1D receptors. Neuropsychopharmacology 25:410-422
5. 1A receptor by clozapine measured using PET scanning (abstract). J Psychopharmacol 14 (Suppl.): PG20
6. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152
7. 1A receptors are not involved in clozapine's lack of cataleptogenic potential. Neuropharmacology 35:1645-1646
8. 3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 30:565-574
9. 1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology 166:234-240
10. 1A receptors expressed in HeLa cells. Eur J Pharmacol 433:55-62
11. 1A receptors. Psychopharmacology 162:168-177
12. 1A receptor-stimulated responses in the human and monkey brain. Eur J Neurosci 11:1809-1817
13. 1A receptors in human post-mortem brain. Eur J Pharmacol 386:313-315
14. 1A-receptor ligands in dorsal raphé and ventral hippocampus. Pharmacol Biochem Behav 54:123-128
15. 1A receptor antagonist. Behav Brain Res 73:337-353
16. 1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416:396-400
17. Harrison PJ (1999) The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 122:593-624
18. 1A receptors in prefrontal cortex and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 48:355-363
19. 1A receptor-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacology 26:565-573
20. 1A receptor function in brain following agonist or antidepressant administration. Life Sci 72:1665-1682
21. 1A agonist, blocks haloperidol-induced catalepsy by an action of raphe nuclei medianus and dorsalis. Neuropharmacology 27:515-518
22. 2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats. Eur J Pharmacol 313:25-34
23. Kroeze WK, Roth BL (1998) The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biol Psychiatry 44:1128-1142
24. B from inhibition curves in functional experiments: alternatives to the Cheng-Prusoff equation. Trends Pharmacol Sci 14:237-239
25. 1A receptors. Eur J Pharmacol 260:79-83
26. 1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats. J Pharmacol Exp Ther 280:1241-1249
27. 1A receptor in the rat hippocampus (abstract). Soc Neurosci Abstract 28:741.12
28. 1A receptors in human brain tissue. Eur J Pharmacol 221:397-398
29. 35S]GTPγS binding in rat brain: absence of regional differences in coupling efficiency. J Pharmacol Exp Ther 292:684-691
30. Menard J, Treit D (1999) Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci Biobehav Rev 23:591-613
31. Meneses A (1999) 5-HT system and cognition. Neurosci Biobehav Rev 23:1111-1125
32. 1A receptors. J Pharmacol Exp Ther 295: 853-861
33. 1A antagonists. J Pharmacol Exp Ther 268:337-351
34. Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet J-M, Cussac D, Nicolas JP, Muller O, Lavielle G (1998a) S16924 ((+)-2-{1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl}-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties. I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 286:1341-1355
35. 1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. J Pharmacol Exp Ther 286:1356-1373
36. Millan MJ, Brocco M, Gobert A, Schreiber R, Dekeyne A (1999a) S16924 ((+)-2-{1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl}-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties. III. Anxiolytic actions in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 288:1002-1014
37. 1B receptors and quantification of G protein coupling to function in corticolimbic structures. Neuropsychopharmacology 21:61S-67S
38. 1A receptor in rat hippocampus. Brain Res 590:229-238
39. 1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635. Br J Pharmacol 120:737-740
40. 1A receptors as a function of receptor:G protein stoichiometry. Neuropharmacology 36:451-459
41. 35S]GTPγS binding study. Eur J Pharmacol 355:245-256
42. 35S]GTPγS. Eur J Pharmacol 384:109-119
43. 2 receptor-mediated G protein activation in the striatum of rats with unilateral 6-hydroxy-dopamine lesions of the substantia nigra pars compacta. Brain Res 920:41-54
44. 3H]WAY100,635. Br J Pharmacol 132:518-524
45. 3H]WAY100,635 binding affinity ratios: relationship to efficacy for G protein activation. Eur J Pharmacol 428: 177-184
46. 1A receptor agonists in recombinant cell lines: modulation of apparent efficacy by G protein activation state. Naunyn-Schmiedeberg's Arch Pharmacol 356: 551-561
47. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic Press, London
48. 1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology 144:20-29
49. 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48:229-237
50. Rowley M, Bristow LJ, Hutson PH (2001) Current and novel approaches to the drug treatment of schizophrenia. J Med Chem 44:477-501
51. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schultz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA, Heym J (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113
52. 1A receptor system: possible implications for schizophrenic negative symptomatology. Psychiatric Ann 26:88-93
53. 35S]GTPγS binding in rat brain regions. Neuropharmacology 42:1031-1038
54. 1A receptor-activated G proteins in the rat brain. Brain Res Bull 44:39-45
55. 35S]GTPγS. Brain Res Rev 38:149-164
56. 1A receptor activation. Neuropsychopharmacology 21:622-631
57. Thielen RJ, Fangon NB, Frazer A (1996) 4-(2′ -Methoxyphenyl)-1-[2′-[N-(2″-pyridinyl)-p-iodobenzamido]ethyl] piperazine and 4-(2′-methoxyphenyl)-1-[2′[N-(2″ -pyridinyl)-p-fluorobenzamido] ethyl]piperazine, two new antagonists at pre- and postsynaptic serotonin-1A receptors. J Pharmacol Exp Ther 277:661-670
58. Wadenberg MLG, Young KA, Richter JT, Hicks PB (1999) Effects of local applications of 5-Hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat. Neuropharmacology 38:151-156
59. 35S]guanosine-5′-O-(3-thio)triphosphate binding to rodent brain sections as visualised by in vitro autoradiography. Mol Pharmacol 52:623-631